Related Experiment Video
Updated: Mar 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Cirrhotic cardiomyopathy
Luis Ruiz-del-Árbol1, Regina Serradilla1
1Luis Ruiz-del-Árbol, Regina Serradilla, Hepatic Hemodynamic Unit, Gastroenterology Department, Hospital Ramón y Cajal, University of Alcalá, 28034 Madrid, Spain.
Insights
Cirrhotic cardiomyopathy involves heart dysfunction, decreased cardiac output, and diastolic issues in cirrhosis patients. Liver transplantation may restore normal heart function.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Background:
- Cirrhosis leads to progressive cardiac dysfunction, including loss of hyperdynamic circulation and decreased cardiac output.
- This cardiac deterioration involves impaired inotropic and chronotropic function, diastolic dysfunction, and cardiac hypertrophy, independent of other heart diseases.
Purpose of the Study:
- To describe the characteristics and pathogenic mechanisms of cirrhotic cardiomyopathy.
- To highlight diagnostic challenges and potential monitoring tools for cirrhotic cardiomyopathy.
- To elucidate the clinical consequences and prognostic implications of cirrhotic cardiomyopathy.
Main Methods:
- Review of existing literature on cirrhotic cardiomyopathy.
- Discussion of diagnostic methods, including echocardiography and the E/e' ratio.
- Exploration of pathogenic mechanisms such as beta-adrenergic signaling impairment and ion channel defects.
Main Results:
- Cirrhotic cardiomyopathy presents with impaired contractile responsiveness and electrophysiological abnormalities like prolonged QT interval.
- Mechanisms include impaired beta-adrenergic signaling, altered cardiomyocyte membrane properties, ion channel defects, and cardiodepressant factors.
- Echocardiography, particularly the E/e' ratio, aids in detecting diastolic dysfunction and monitoring disease progression.
Conclusions:
- Cirrhotic cardiomyopathy significantly contributes to impaired arterial blood volume and correlates with liver failure severity.
- Cardiac dysfunction can lead to renal hypoperfusion and renal failure.
- While treatment is non-specific, liver transplantation offers potential for normalizing cardiac function.
Abstract:
During the course of cirrhosis, there is a progressive deterioration of cardiac function manifested by the disappearance of the hyperdynamic circulation due to a failure in heart function with decreased cardiac output. This is due to a deterioration in inotropic and chronotropic function which takes place in parallel with a diastolic dysfunction and cardiac hypertrophy in the absence of other known cardiac disease. Other findings of this specific cardiomyopathy include impaired contractile responsiveness to stress stimuli and electrophysiological abnormalities with prolonged QT interval. The pathogenic mechanisms of cirrhotic cardiomyopathy include impairment of the b-adrenergic receptor signalling, abnormal cardiomyocyte membrane lipid composition and biophysical properties, ion channel defects and overactivity of humoral cardiodepressant factors. Cirrhotic cardiomyopathy may be difficult to determine due to the lack of a specific diagnosis test. However, an echocardiogram allows the detection of the diastolic dysfunction and the E/e' ratio may be used in the follow-up progression of the illness. Cirrhotic cardiomyopathy plays an important role in the pathogenesis of the impairment of effective arterial blood volume and correlates with the degree of liver failure. A clinical consequence of cardiac dysfunction is an inadequate cardiac response in the setting of vascular stress that may result in renal hypoperfusion leading to renal failure. The prognosis is difficult to establish but the severity of diastolic dysfunction may be a marker of mortality risk. Treatment is non-specific and liver transplantation may normalize the cardiac function.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Rheumatic Heart Disease I: Introduction

